This podcast features two oncologists discussing current and emerging treatment options for patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) after progression on osimertinib and platinum-based chemotherapy (PBC).

The existing treatment landscape for EGFR-mutated NSCLC following osimertinib and PBC is highly fragmented, and subsequent treatments provide modest clinical benefit coupled with substantial toxicity.

New effective and safe therapies are needed; emerging therapeutic candidates are being investigated in clinical trials as potential treatment options to overcome resistance to existing treatments and to improve clinical outcomes.

Molecular testing can aid in the monitoring of disease progression, as well as providing insights into the selection of subsequent treatments.